Characteristics of the main cohort and the subsets based on asparaginase truncation
| Characteristics . | Main cohort . | Truncated . | Nontruncated . |
|---|---|---|---|
| No. of patients (%) | 1401 | 358 (25.6) | 1043 (74.4) |
| Age at diagnosis, y | |||
| Median [IQR] | 4 [2-8] | 4 [2-8.75] | 4 [2-8] |
| <10, no. (%) | 1118 (79.8) | 279 (77.9) | 839 (80.4) |
| ≥10, no. (%) | 283 (20.2) | 79 (28.3) | 204 (19.6) |
| Sex, no. (%) | |||
| Male | 765 (54.6) | 193 (53.9) | 572 (54.8) |
| Female | 636 (45.4) | 165 (46.1) | 471 (45.2) |
| NOPHO risk group, no. (%) | |||
| SR | 716 (51.1) | 173 (48.3) | 543 (52.1) |
| IR | 495 (35.3) | 123 (34.4) | 372 (35.7) |
| HR | 190 (13.6) | 62 (17.3) | 128 (12.3) |
| NCI risk group, no. (%) | |||
| SR | 884 (63.1) | 219 (61.2) | 665 (63.8) |
| HR | 517 (36.9) | 139 (38.8) | 378 (36.2) |
| CNS status at diagnosis, no. (%) | |||
| CNS 1 | 1225 (87.4) | 309 (86.3) | 916 (87.8) |
| CNS 2 | 113 (8.1) | 31 (8.7) | 82 (7.9) |
| CNS 3 | 61 (4.4) | 16 (4.5) | 45 (4.3) |
| Missing value | 2 (0.1) | 2 (0.6) | — (—) |
| MRD group, day 29, no. (%) | |||
| MRD 1 | 382 (27.3) | 107 (29.9) | 275 (26.4) |
| MRD 2 | 324 (23.1) | 78 (21.8) | 246 (23.6) |
| MRD 3 | 145 (10.3) | 39 (10.9) | 106 (10.2) |
| MRD 4 | 525 (37.5) | 127 (35.5) | 398 (38.2) |
| Missing value | 25 (1.8) | 7 (2.0) | 18 (1.7) |
| WBC at diagnosis, 109/L | |||
| Median [IQR] | 10.9 [4.5-39.5] | 13.0 [4.6-40.4] | 10.5 [4.5-37.5] |
| Asp. doses given* | |||
| Median [IQR] | 15 [8-15] | 4 [3-7] | 15 [8-15] |
| Characteristics . | Main cohort . | Truncated . | Nontruncated . |
|---|---|---|---|
| No. of patients (%) | 1401 | 358 (25.6) | 1043 (74.4) |
| Age at diagnosis, y | |||
| Median [IQR] | 4 [2-8] | 4 [2-8.75] | 4 [2-8] |
| <10, no. (%) | 1118 (79.8) | 279 (77.9) | 839 (80.4) |
| ≥10, no. (%) | 283 (20.2) | 79 (28.3) | 204 (19.6) |
| Sex, no. (%) | |||
| Male | 765 (54.6) | 193 (53.9) | 572 (54.8) |
| Female | 636 (45.4) | 165 (46.1) | 471 (45.2) |
| NOPHO risk group, no. (%) | |||
| SR | 716 (51.1) | 173 (48.3) | 543 (52.1) |
| IR | 495 (35.3) | 123 (34.4) | 372 (35.7) |
| HR | 190 (13.6) | 62 (17.3) | 128 (12.3) |
| NCI risk group, no. (%) | |||
| SR | 884 (63.1) | 219 (61.2) | 665 (63.8) |
| HR | 517 (36.9) | 139 (38.8) | 378 (36.2) |
| CNS status at diagnosis, no. (%) | |||
| CNS 1 | 1225 (87.4) | 309 (86.3) | 916 (87.8) |
| CNS 2 | 113 (8.1) | 31 (8.7) | 82 (7.9) |
| CNS 3 | 61 (4.4) | 16 (4.5) | 45 (4.3) |
| Missing value | 2 (0.1) | 2 (0.6) | — (—) |
| MRD group, day 29, no. (%) | |||
| MRD 1 | 382 (27.3) | 107 (29.9) | 275 (26.4) |
| MRD 2 | 324 (23.1) | 78 (21.8) | 246 (23.6) |
| MRD 3 | 145 (10.3) | 39 (10.9) | 106 (10.2) |
| MRD 4 | 525 (37.5) | 127 (35.5) | 398 (38.2) |
| Missing value | 25 (1.8) | 7 (2.0) | 18 (1.7) |
| WBC at diagnosis, 109/L | |||
| Median [IQR] | 10.9 [4.5-39.5] | 13.0 [4.6-40.4] | 10.5 [4.5-37.5] |
| Asp. doses given* | |||
| Median [IQR] | 15 [8-15] | 4 [3-7] | 15 [8-15] |
Asp., asparaginase; HR, high risk; IQR, interquartile range.
PEG-asparaginase doses including recalculated Erwinia asparaginase doses (6 doses of Erwinia asparaginase corresponds to 1 dose of PEG-asparaginase).